In a regulatory filing, Japan's Daiichi Sankyo said that its board has agreed to it selling some or all of its shares in Sun Pharmaceutical, which Reuters reports are now worth about $3.6 billion. No reason was given, the news service said, but its experience with Ranbaxy, which was recently acquired by Sun, has been nonstop issues.
Daiichi Sankyo has had enough of trying to make money in the Indian generic drug industry. The Japanese drugmaker, which faces patent cliff issues, is selling off its stake in Sun Pharmaceutical just weeks after it closed on the all-stock deal selling Ranbaxy Laboratories to Sun for $3.2 billion.
With what for most of them is a new fiscal year, drug companies in Asia rolled out a series of deals and other actions, among them a submerger of a sort, a buyout, a research agreement and a housecleaning.
In one of its first acts as India's new leading drugmaker, Sun Pharmaceuticals announced the beginning of the end of Ranbaxy Laboratories by removing the company from the stock markets after trading has ended on April 1.
Times have been tough for Daiichi Sankyo, and they're about to get tougher for some of the Japanese company's U.S. staffers. The drugmaker is cutting its headquarters staff by 16% on Monday, with more layoffs expected in mid-April.
AstraZeneca has decided not to go it alone on marketing Movantik. Daiichi Sankyo has signed on to help launch the constipation pill--and it's paying a pretty penny for the opportunity.
AstraZeneca announced a partnership with Daiichi Sankyo to sell its opioid-induced constipation therapy Movantik in the U.S. for a $200 million upfront fee from the Japanese drugmaker followed by sales-related payments of up to $625 million.
Two months after settlement of a $39 million Medicaid-related U.S. government suit was disclosed by Daiichi Sankyo, the details of the civil suit against the Japan-based drugmaker were laid out by the New York state's attorney general's office.
Japan's Takeda Pharmaceutical has looked at Indian companies in the vaccine space as it moves to tighten focus on that aspect of its business ahead of a Phase III trial for a dengue candidate and more broadly emerging markets as seen by a recent M&A deal in Turkey.
Daiichi Sankyo has revamped management roles and will cut reporting lines on April 1, ahead of the looming loss of its patent protection of flagship hypertension drug olmesartan (Benicar) in key markets this year to shore up its group structure.